Combination of local and systemic immunomodulative therapies for melanoma and liver cancer
View Patent ↗A method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic immunomodulatory anticancer agent. A further method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic targeted anticancer agent. The present invention is further directed to pharmaceutical compositions for treatment of cancer. The intralesional chemoablative pharmaceutical composition can comprise an IL chemoablative agent comprising primarily a halogenated xanthene.
1. A method of treatment of a melanoma, or a primary or metastatic liver cancer tumor in a human comprising separately administering a therapeutically effective amount of: (1) an intralesional chemoablative pharmaceutical composition to elicit ablation of at least one melanoma, or primary or metastatic liver cancerous tumor; and (2) a therapeutically effective amount of a systemic immunomodulatory anticancer agent that comprises interferon-gamma, anti-CTLA-4 antibodies, anti-PD-L1 antibodies or anti-PD-1 antibodies,
wherein said intralesional chemoablative pharmaceutical composition comprises an intralesional (IL) chemoablative agent comprising rose bengal (4,5,6,7-tetrachloro-2′,4′,5′,7′-tetraiodofluorescein) in an appropriate pharmaceutical composition, including a 0.1% (w/v) or higher concentration aqueous solution of rose bengal, or a physiologically acceptable salt of rose bengal, said intralesional chemoablative pharmaceutical composition being administered intralesionally into said at least one melanoma, or primary or metastatic liver cancerous tumor at about 0.1 mL/cc lesion volume to about 2 mL/cc lesion volume.
2. The method of claim 1 , wherein said systemic immunomodulatory anticancer agent that is a systemic inhibitor of immune system down-regulation comprises anti-CTLA-4 antibodies.
3. The method of claim 1 , wherein the rose bengal salt is rose bengal disodium.
4. The method of claim 1 , wherein said rose bengal is present at a concentration of about 0.1% (w/v) up to about 20% (w/v), and the pharmaceutical composition includes an electrolyte comprising at least one cation selected from the group consisting of sodium, potassium, calcium and magnesium and at least one anion selected from the group consisting of chloride, phosphate and nitrate, wherein the electrolyte is at a concentration of between about 0.1% (w/v) and about 2% (w/v).
5. The method of claim 4 , wherein the concentration of said electrolyte in the IL chemoablative pharmaceutical composition is between 0.5 to 1.5% (w/v).
6. The method of claim 1 , wherein said chemoablative pharmaceutical composition has an osmolality of the composition of greater than about 100 mOsm/kg.
7. The method of claim 4 , wherein said electrolyte is sodium chloride.
8. The method of claim 1 , wherein said pharmaceutical composition comprises a hydrophilic vehicle.
9. The method of claim 1 , wherein said pharmaceutical composition has a pH in the range of between about 4 to about 10.
10. The method of claim 9 , wherein said pharmaceutical composition has a pH in the range of between about 5 to about 7.
11. A method of treatment of a melanoma, or primary or metastatic liver cancer tumor in a human comprising separately administering a therapeutically effective amount of: (1) an intralesional chemoablative pharmaceutical composition to elicit ablation of at least one melanoma, or primary or metastatic liver cancerous tumor; and (2) a therapeutically effective amount of a systemic immunomodulatory anticancer agent that comprises interferon-gamma, anti-CTLA-4 antibodies, anti-PD-L1 antibodies or anti-PD-1 antibodies, wherein said intralesional chemoablative pharmaceutical composition comprises an intralesional (IL) chemoablative agent comprising a halogenated xanthene in an appropriate pharmaceutical composition, including a 0.1% (w/v) or higher concentration aqueous solution of the halogenated xanthene or mixtures thereof, or a physiologically acceptable salt of the halogenated xanthene.
12. The method of claim 11 , wherein the halogenated xanthene is selected from the group consisting of erythrosin B, phloxine B, 4,5,6,7-tetrabromo-2′,4′,5′,7′-tetraiodofluorescein, 2′,4,5,6,7-pentachloro-4′,5′,7′-triiodofluorescein, 4,4′,5,6,7-pentachloro-2′,5′,7′-triiodofluorescein, 2′,4,5,6,7,7′-hexachloro-4′,5′-diiodofluorescein, 4,4′,5,5′,6,7-hexachloro-2′,7′-diiodofluorescein, 2′,4,5,5′,6,7-hexachloro-4′,7′-diiodofluorescein, 4,5,6,7-tetrachloro-2′,4′,5′-triiodofluorescein, 4,5,6,7-tetrachloro-2′,4′,7′-triiodofluorescein, 4,5,6,7-tetrabromo-2′,4′,5′-triiodofluorescein, and 4,5,6,7-tetrabromo-2′,4′,7′-triiodofluorescein.
13. The method of claim 11 , wherein the halogenated xanthene is rose bengal (4,5,6,7-tetrachloro-2′,4′,5′,7′-tetraiodofluorescein) or a physiologically acceptable salt of rose bengal.
14. The method of claim 13 wherein the halogenated xanthene is rose bengal disodium.
15. The method of claim 11 , wherein said rose bengal is present at a concentration of about 0.1% (w/v) up to about 20% (w/v), and the pharmaceutical composition includes an electrolyte comprising at least one cation selected from the group consisting of sodium, potassium, calcium and magnesium and at least one anion selected from the group consisting of chloride, phosphate and nitrate, wherein the electrolyte is at a concentration of between about 0.1% (w/v) and about 2% (w/v).
16. The method of claim 15 , wherein the concentration of said electrolyte in the IL chemoablative pharmaceutical composition is between 0.5 to 1.5% (w/v).
17. The method of claim 16 , wherein said chemoablative pharmaceutical composition has an osmolality of the composition of greater than about 100 mOsm/kg.
18. The method of claim 15 , wherein said electrolyte is sodium chloride.
19. The method of claim 11 , wherein said pharmaceutical composition comprises a hydrophilic vehicle.
20. The method of claim 11 , wherein said pharmaceutical composition has a pH value in the range of about 4 to about 10.
21. The method of claim 20 , wherein said pharmaceutical composition has a pH value in the range of about 5 to about 7.
22. The method of claim 11 , wherein said systemic immunomodulatory anticancer agent comprises one or more of anti-CTLA-4 antibodies, anti-PD-L1 antibodies or anti-PD-1 antibodies.
23. The method of claim 22 , wherein said administration of said systemic immunomodulatory anticancer agent is commenced prior to administration of said intralesional chemoablative pharmaceutical composition.
24. The method of claim 23 , wherein the rose bengal salt is rose bengal disodium.
25. A method of treatment of a melanoma, or a primary or metastatic liver cancer tumor in a human comprising separately administering a therapeutically effective amount of: (1) an intralesional chemoablative pharmaceutical composition to elicit ablation of at least one melanoma, or primary or metastatic liver cancerous tumor; and (2) a therapeutically effective amount of a systemic immunomodulatory anticancer agent that is a systemic inhibitor of immune system down-regulation or that is a systemic enhancer of immune system up-regulation in a combination therapeutic regimen,
wherein said intralesional chemoablative pharmaceutical composition comprises an intralesional (IL) chemoablative agent comprising rose bengal (4,5,6,7-tetrachloro-2′,4′,5′,7′-tetraiodofluorescein) in an appropriate pharmaceutical composition, including a 0.1% (w/v) or higher concentration aqueous solution of rose bengal, or a physiologically acceptable salt of rose bengal, said intralesional chemoablative pharmaceutical composition being administered intralesionally into said at least one melanoma, or primary or metastatic liver cancerous tumor at about 0.1 mL/cc lesion volume to about 2 mL/cc lesion volume, and
wherein said systemic immunomodulatory anticancer agent that is a systemic inhibitor of immune system down-regulation comprises anti-CTLA-4 antibodies, anti-PD-L1 antibodies or anti-PD-1 antibodies.